US FDA approves Novartis's Reclast for osteoporosis prevention
This article was originally published in Scrip
Executive Summary
The US FDA has approved Novartis's intravenous bisphosphonate Reclast (zoledronic acid) for the prevention of postmenopausal osteoporosis in women with osteopenia (low bone mass).